GreenRoc Accelerates their World Class Project to Production as Early as 2028. Watch the full video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksIDP.L Regulatory News (IDP)

  • There is currently no data for IDP

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Trading Statement

9 Jan 2020 07:00

RNS Number : 1997Z
InnovaDerma PLC
09 January 2020
 

LEI: 213800WRAP6W8VDL6B38

InnovaDerma PLC

("InnovaDerma" or the "Company")

Trading Statement

InnovaDerma (LSE: IDP), a UK developer of beauty, personal care and life sciences products, provides a trading update for the six months ended 31 December 2019.

The Company generated revenues of £5.0m, up c.28% compared to the same period last year (H1 2019: £3.9m). The increase in revenue was driven predominantly by Skinny Tan and its performance on the Company's DTC platform and in the UK retail channel. The former has continued to benefit from a revised digital engagement strategy and investment in all three key geographical markets: UK, US and Australia. Product innovation remains key to the business and the first six months included the launch of the limited-edition Choc range in Superdrug, which resulted in exceptional demand and the continued success of Wonder Serum in Boots has provided a strong platform for the season ahead. These initiatives have alleviated the effects of a softer UK high street retail environment and shelf space rationalisation, typical of seasonal products such as Skinny Tan.

The UK DTC channel accounted for 56% of total revenue (H1 2019: 59%). Skinny Tan DTC revenue was supported by Black Friday and Christmas promotions, up c.27% compared to the same period last year. UK retail revenue was almost double that of H1 2019, driven by the Skinny Tan rollout into Boots' stores, an opening order from Tesco, and continued support from Superdrug. Pleasingly, our core brand also made excellent progress in Australia and the US DTC markets, with the introduction of new products. Whilst these two territories remain a small proportion of our overall revenue, growth was robust.

Roots revenues were lower than expected due to competitive shelf positioning, however, new products, particularly Platinum Colour Protect, performed well. Charles + Lee continued to build momentum with Australian retailers and almost doubled revenues compared to last year.

Life Sciences' revenue increased by 71% on the previous year as a result of DTC sales driven by online 'influencers', predominantly in the US.

As in previous years, the Company expects revenue and profit growth to be strongly weighted to H2 FY2020, reflecting the peak tanning season. Skinny Tan remains well positioned to perform well in the UK despite a challenging outlook for the UK retail market. Charles & Lee is growing in popularity, and we look forward to expanding its geographical spread. Roots will receive extra marketing and product development focus to expand its customer base and product offering in 2020.

The momentum of the first half coupled with our forthcoming new category launch give us much confidence for the full year. The balance sheet remains healthy and with an increased retail footprint coupled with continued focus on our DTC channels in core regions, the Company expects to generate strong revenue and profit growth in the second half of the year.

This announcement contains inside information for the purposes of Article 7 of EU Regulation 596/2014.

Further enquiries

InnovaDerma

Joe Bayer

Kieran Callan c/o TB Cardew

www.innovaderma.com

 

 

+61 (0)3 9863 8030

+44 (0)20 7930 0777

finnCap Ltd

Geoff Nash/ Kate Bannatyne

Alice Lane/Manasa Patil - Corporate Broking

 

 

+44 (0)207 220 0500

www.finncap.com

TB Cardew

Shan Shan Willenbrock/Tom Allison

Olivia Rosser

 

+ 44 (0)20 7930 0777

innovaDerma@tbcardew.com

 

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
 
END
 
 
TSTKKFBNPBKDCDK
Date   Source Headline
12th Jan 20227:00 amRNSTrading Update
6th Jan 20222:06 pmRNSSecond Price Monitoring Extn
6th Jan 20222:01 pmRNSPrice Monitoring Extension
4th Jan 20227:00 amRNSAcquisition of Remaining Shareholding - Skinny Tan
24th Dec 202112:44 pmRNSHolding(s) in Company
24th Dec 202112:41 pmRNSDirector/PDMR Shareholding
23rd Dec 20211:22 pmRNSNotice of AGM and Posting of Annual Report
20th Dec 20219:10 amRNSFinal Results
6th Dec 20217:00 amRNSJV established to accelerate growth of Prolong
22nd Oct 20217:00 amRNSExtension to Annual Report & Accounts Publication
12th Oct 20217:00 amRNSAppointment of Skinny Tan brand ambassador
16th Sep 202111:17 amRNSDirector/PDMR Shareholding
15th Sep 20217:00 amRNSHolding(s) in Company
13th Sep 20216:24 pmRNSHolding(s) in Company
7th Sep 202110:35 amRNSDirector/PDMR Shareholding
2nd Sep 20217:00 amRNSCorporate Update
8th Jul 20217:00 amRNSTrading Statement
5th Jul 20217:00 amRNSChange of Auditor
11th May 20216:15 pmRNSDirector/PDMR Shareholding
7th May 202111:05 amRNSSecond Price Monitoring Extn
7th May 202111:00 amRNSPrice Monitoring Extension
4th May 20215:12 pmRNSHolding(s) in Company
29th Apr 202112:24 pmRNSResult of Open Offer and General Meeting
29th Apr 20217:00 amRNSGeneral Meeting and Trading Statement
19th Apr 20214:41 pmRNSSecond Price Monitoring Extn
19th Apr 20214:35 pmRNSPrice Monitoring Extension
16th Apr 202111:00 amRNSDirector/PDMR Shareholding
12th Apr 20216:19 pmRNSPublication of Prospectus
12th Apr 20217:00 amRNSExpected Timetable of Events
31st Mar 20217:00 amRNSInterim Results
22nd Mar 20212:25 pmRNSNotice of Results, Prospectus and General Meeting
24th Feb 20215:09 pmRNSForm 8.3 - Offeree Innovaderma
24th Feb 20214:47 pmRNSForm 8.3 - InnovaDerma PLC
23rd Feb 20211:51 pmRNSForm 8.3 - InnovaDerma PLC
22nd Feb 20214:48 pmRNSForm 8.3 - Innovaderma
19th Feb 20214:13 pmRNSForm 8.3 - Innovaderma PLC
18th Feb 20217:00 amRNSForm 8.3 - InnovaDerma PLC
17th Feb 20215:23 pmRNSForm 8.3 - InnovaDerma PLC
17th Feb 202112:37 pmRNSForm 8.3 - InnovaDerma
16th Feb 20216:23 pmRNSForm 8.3 - InnovaDerma PLC
16th Feb 202112:33 pmRNSForm 8.3 - InnovaDerma
16th Feb 202110:52 amRNSForm 8.3 - Innovaderma Plc
16th Feb 202110:06 amRNSForm 8.3 - Innovaderma PLC
16th Feb 20219:05 amBUSForm 8.3 - INNOVADERMA PLC - AMENDMENT
15th Feb 20216:12 pmRNSForm 8.3 - InnovaDerma
15th Feb 20215:03 pmRNSForm 8.3 - InnovaDerma Plc
15th Feb 20215:02 pmRNSHolding(s) in Company
15th Feb 20214:47 pmRNSForm 8 (OPD) - InnovaDerma plc
15th Feb 20213:40 pmRNSForm 8.3 - InnovaDerma PLC
15th Feb 20212:54 pmRNSForm 8.3 - InnovaDerma PLC

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.